Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04893447 · ClinicalTrials.gov registry record · NA
Suicide Prevention Among Recipients of Care
A NA study, sponsored by St. Luke's Health System, Boise, Idaho.
- Completed
- Registry status
- NA
- Development phase
- 1,520
- Enrollment target
NCT04893447: Completed NA study, sponsored by St. Luke's Health System, Boise, Idaho.
NCT04893447 is a NA study that has completed, run by St. Luke's Health System, Boise, Idaho. The registered enrollment target is 1,520 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04893447, a NA study, has completed, sponsored by St. Luke's Health System, Boise, Idaho.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,520 participants
- Enrollment target
Study Summary
Randomized controlled trial to determine the best brief suicide prevention intervention for adults and adolescents who screen positive for suicidal ideation or behavior in emergency departments or primary care clinics. Aim 1: Compare the effectiveness of two brief suicide prevention interventions (safety planning intervention plus structured phone-based follow-up from a suicide prevention hotline (SPI+), versus safety planning intervention plus caring contacts (CC)) to (a) reduce suicidal ideation and behavior, (b) reduce loneliness, (c) reduce return to care for suicidality, and (d) increase uptake of outpatient mental healthcare services over 12 months among adult and adolescent patients screening positive for suicide in emergency departments (EDs) and primary care clinics. Aim 2: Assess the acceptability of connection and support planning and the safety planning intervention, with or without follow-up among providers and clinical staff in EDs and primary care clinics. Aim 3: Assess the acceptability of SPI+ and SP+CC among adult and adolescent patients.
Primary Outcome
6-item questionnaire with yes/no response options. Scores range from 0 (no risk) to 6 (high risk)
Interventions
- BEHAVIORAL SPI+
- BEHAVIORAL SP+CC (Caring Contacts)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,520 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2024-07-07 |
| Phase | NA |
What the finished NCT04893447 record still lists
NCT04893447 is an interventional study that assigns participants to a tested intervention. Its 1,520 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which SPI+ is the first listed.
NCT04893447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04893447 about?
NCT04893447 is a clinical study titled "Suicide Prevention Among Recipients of Care". Randomized controlled trial to determine the best brief suicide prevention intervention for adults and adolescents who screen positive for suicidal ideation or behavior in emergency departments or primary care clinics. Aim 1: Compare the effectiveness of two brief suicide prevention interventions (...
What is the current status of trial NCT04893447?
This trial is currently completed. It is a NA study. The enrollment target is 1,520 participants. The study started on 2021-05-20. Estimated completion is 2024-07-07.
What interventions are being tested in trial NCT04893447?
The interventions under investigation include: SPI+ (BEHAVIORAL), SP+CC (Caring Contacts) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04893447?
This trial is sponsored by St. Luke's Health System, Boise, Idaho, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04893447's enrollment target sits among peer trials
1,520 65th of 2000 higher than 1,936 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- NCT06257082 · 1,526 participants · NA
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI